n the last two decades, a plethora of magnetic resonance (MR) techniques have been introduced to provide indispensable measurement capabilities for studies of the brain in humans and in animal models of human diseased states. In addition to the exquisite anatomical information provided by MRI, these capabilities include imaging of brain function (functional MRI-fMRI), perfusion, vascular anatomy, diffusion, neurochemistry, and metabolic rates. At the same time, substantial gains in sensitivity and resolution with increasing magnetic field strength have been demonstrated (eg, ref 1) facilitating new discoveries as well as more robust preclinical and clinical applications of these techniques. Animal model
A plethora of magnetic resonance (MR) techniques developed in the last two decades provide unique and noninvasive measurement capabilities for studies of basic brain function and brain diseases in humans. Animal model experiments have been an indispensible part of this development. MR imaging and spectroscopy measurements have been employed in animal models, either by themselves or in combination with complementary and often invasive techniques, to enlighten us about the information content of such MR methods and/or verify observations made in the human brain. They have also been employed, with or independently of human efforts, to examine mechanisms underlying pathological developments in the brain, exploiting the wealth of animal models available for such studies.
In this endeavor, the desire to push for ever-higher spatial and/or spectral resolution, better signal-to-noise ratio, and unique image contrast has inevitably led to the introduction of increasingly higher magnetic fields. As a result, today, animal model studies are starting to be conducted at magnetic fields ranging from ~11 to 17 Tesla, significantly enhancing the armamentarium of tools available for the probing brain function and brain pathologies. studies have been an indispensible to these advances, particularly as part of efforts focused on increasing the magnetic field strength of human MR experiments. High field human studies started with the use of 4 Tesla (T) in 1991, when MR instruments employed in human imaging operated at 1.5 T or less. Ultimately, 7 T and, to a much lesser extent, to 9.4 T was established for human studies, largely justified by results obtained in animal model systems at such magnetic fields. 2 Subsequent to the initial explorations of 4 T for human brain studies, a 9.4 T system was introduced for the first time for animal model experiments. This prototype instrument, with a bore large enough to perform studies in small-to medium-sized animals (eg, rodents and cats), provided the early forays (eg, refs [3] [4] [5] [6] into the exploration of ultrahigh magnetic fields for functional, anatomical, and biochemical measurements in animal models using MR methods. Note that the terminology is based on classification of radiofrequency (RF) bands. The frequency range 300 MHz to 3 GHz is defined as ultra high frequency (UHF)-http://en.wikipedia.org/wiki/Ultra_high_fre-quency. The hydrogen nucleus resonance frequency at 7 T is ~300 MHz, ie, in the UHF band. Therefore, 7 to 70 T is defined as ultrahigh field (UHF). This body of work offered a clear demonstration of the advantages inherent at such fields and ultimately led to the development of instruments operating at even higher magnetic fields, such as 11.7, 14, 16.4 , and 17 T. These ultrahigh field scanners provided significant and necessary new gains in resolution and sensitivity for animal model experiments.
High field MR imaging

Functional imaging
The effort to pursue high magnetic fields has been intricately tied to introduction of fMRI that can generate maps of human brain activity noninvasively. The very first fMRI experiments [7] [8] [9] [10] were conducted at two different magnetic fields, 4 T and 1.5 T, providing the initial evidence that functional imaging may improve with increasing magnetic field strength; the results obtained at 4 T were at higher resolution and largely followed the contours of the gray matter ribbon, whereas the 1.5 T images of increased brain activity were more diffuse. 2 This field dependence was anticipated based on mathematical modeling 11 of the blood oxygenation leveldependent (BOLD) effect, which is based on the magnetic susceptibility difference between the intra-and extravascular space of deoxyhemoglobin containing blood vessels. This and other early (eg, refs [12] [13] [14] computational models of the BOLD phenomenon are currently understood to be largely accurate, albeit incomplete with respect to the mechanisms contributing to functional mapping signals. Some of these initially overlooked mechanisms (eg, inflow effects) form the basis of the successful use of lower field strengths, such as 1.5 T, for the acquisition of functional images in human brain. Nevertheless, increased understanding of the origin of fMRI signals (see ref 15 and references therein) have also reconfirmed original expectations that there are major advantages in going to very high magnetic fields, and these have largely been experimentally verified by a plethora of studies conducted with animal models (eg, refs 1, 16-18) . For example, in fMRI, the contrast-to-noise ratio (CNR) of deoxyhemoglobin-based BOLD mapping signals increases linearly in high-resolution imaging for gradient echo (GE)-based techniques, the predominant approach employed in contemporary fMRI experiments. (Contrast in fMRI is defined as the magnitude of the signal change induced by a stimulus or a task. Contrast-to noise ratio CNR is the ratio of the contrast to the signal fluctuations in the fMRI time series). When image resolution is high, the latter is dominated by the "thermal" noise present in each image of the time series. At low resolution, CNR for GE fMRI increases less than linearly with field magnitude since the temporal fluctuations of signals become dominated by physiological processes (rather than thermal noise) and display a dependence on signal amplitude, hence magnetic field magnitude. For spin echo (SE) BOLD fMRI, which provides more accurate functional localization, 1, 16, 17 albeit only at high magnetic fields and with smaller signal changes 1, 9, 20 CNR can exhibit more than a linear dependence on magnetic field magnitude because of supralinear gains in fractional signal change induced by neuronal activity 19, 20 and a linear elevation in intrinsic image signal-to-noise ratio (SNR). 21 The gains in fractional signal change, however, tend to level off at fields above ~9 to 10 Tesla, 15 leaving the SNR gains as the only potential source of CNR improvements. More importantly, however, higher magnetic fields provide significantly better spatial fidelity in the deoxyhemoglobin-based functional mapping signals (eg, refs 1, 16, 17) . fMRI relies on secondary metabolic and vascular responses invoked by alterations in neuronal activity. Therefore, its accuracy can be degraded by limitations imposed by these secondary responses. However, in a critical experiment performed in the cat visual cortex, it was demonstrated that blood flow increase induced by functional activation is regulated at the level of orientation columns. This observation indicated for the first time that cerebral blood flow (CBF) must be controlled at the capillary level, contradicting the accepted concept of the time that the "brain waters an entire garden for the sake of a single thirsty flower." Instead, these crucial animal model studies 22 suggested that the "brain waters specifically the thirsty flower, but also sprinkles the surrounding garden." The definitive conclusion of these cat visual cortex experiments was that the secondary physiological responses to neuronal activity would be compatible with very high-resolution functional mapping with CBF-based fMRI and potentially with BOLD based fMRI. Compared with CBF methods, however, the BOLD approach suffers from additional confounds that can obfuscate spatial fidelity. They arise because blood vessels mediate the coupling between the physiological changes and the MR-detected functional signals; this coupling depends in a complex way on the diameter and oxygenation levels of the blood vessel involved (eg, refs 15,23,24) . The consequences of these confounds were evaluated experimentally, most notably in animal models, but in humans as well. The point spread function (PSF) of the conventional GE fMRI was measured to be ~3.5 mm (full width at half maximum [FWHM] ) 25 at 1.5 T and ~2.5 mm at 4.7 T. 26 In contrast, the PSFs (FWHM) were reported as 1.64 ± 0.11 mm and 0.67 ± 0.08 for GE and SE fMRI, respectively, at 9.4 T in the cat visual cortex. 27, 28 With a PSF of ~0.7 mm, columnar organization in 1 mm spatial scale and cortical laminar differentiations is easily possible without significant blurring. This has been demonstrated for several elementary organizations at the level of cortical layers 19, [29] [30] [31] [32] and cortical columns 30, [33] [34] [35] [36] [37] [38] [39] in parallel studies conducted in the human brain and in the brain of animal model systems. [40] [41] [42] [43] [44] [45] [46] Figure 1 illustrates an example from work examining laminar specificity in cat visual cortex using concurrent MR and histology studies. 44 For animal model studies only, a highly desirable alternative to BOLD fMRI is cerebral blood volume (CBV)-based imaging using exogenous, intravascular contrast agents, typically superparamagnetic iron oxide particles, employed in high doses. This approach has been employed in studies ranging from rodents to the nonhuman primate (eg, refs 40, 44, [47] [48] [49] , and was shown to have specificity to cortical layers and orientation columns. 40 The magnetization of iron oxide agents saturate 47 at a relatively low magnetic field strength; as such, functional contrast arising from their presence does not increase significantly with increasing magnetic fields. Nevertheless, CNR for functional mapping has been reported to be about ~5 47 and ~3 times 49 higher with such agents compared with BOLD-based fMRI at low (1.5 -2 T), and intermediate fields (3 -4.7 T), respectively. It is possible that BOLD contrast will increase sufficiently at ultrahigh fields such as ~14 to 17 T so that it will in fact provide a preferable approach to iron oxide particles. However, neither these extremely high fields nor the use of these exogenous particles at such high doses are available for human brain studies. The former because such magnets with a large enough bore to accommodate humans remain beyond the scope of contemporary technology, and the latter because of potential toxicity concerns. Therefore, these technologies will remain applicable only to animal model studies for the foreseeable future. To date, the vast majority of information accumulated about brain function is based on electrophysiological recordings of single-and multiple-unit activities in animal models, for example in instrumented, behaving nonhuman primates. Consequently, it was inevitable that the relationship between electrophysiological and fMRI data would be examined. Such experiments were naturally performed in animal models, continuing the trend of combining invasive but often more informative measurements with the noninvasive fMRI method. In simultaneously acquired data, the spiking activity and local field potentials recorded with implanted electrodes in the nonhuman primate were compared with BOLD fMRI signal changes during visual stimulation, 50, 51 indicating that local field potentials rather than spiking activity correlates with the BOLD fMRI signals. A similar strategy was employed in the cat visual cortex to examine the spatial relationship between single-unit activity and stimulus-induced fMRI maps obtained at 9.4 T. 52 When averaged over ~4x4 mm 2 cortical surface area, spiking activity and fMRI signals were found to be well correlated, but the correlation broke down progressively with diminishing surface area over which the averaging was performed. Especially at the level of individual electrode recording sites, the correlation between the two signals varied substantially because of the spatial inaccuracies inherent in GE BOLD fMRI. 52 The electrophysiological recordings have also been employed to probe neuronal mechanisms underlying resting state fMRI (rfMRI) in animal models. (eg, refs 53-56). Unlike task-or stimulus-induced fMRI, rfMRI uses correlations in the spontaneous temporal fluctuations in an fMRI time series to deduce "functional connectivity"; it serves as an indirect but nonetheless invaluable indicator of gray-matter regions that interact strongly and, in many cases, are connected anatomically (eg, refs 57-62). Many of these studies reported a correlation between fluctuations in rfMRI signals and concurrent fluctuations in the underlying, neuronal activity measured locally with multiunit electrodes. Such combined approaches continue to be used in animal models to probe numerous aspects of brain function, as well as the properties of functional imaging data; however, the literature in this field is too vast to cover comprehensively in this brief review.
Structural MRI
Structural MRI is increasingly accepted as a surrogate for anatomic phenotype in neuroscience research. In many areas, anatomic MRI has replaced the need for analysis of the postmortem brain in order to elucidate relationships between structure and function. It is not hard to find examples in which anatomic MRI has transformed the entire research landscape of a field: cerebrovascular disease, epilepsy, multiple sclerosis, and other inflammatory conditions, cerebral developmental disorders, to some extent psychiatric disorders, and neurodegenerative disorders. Animal model studies at high
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T r a n s l a t i o n a l r e s e a r c h ) maps for a 40-s drifting bars stimuli. Signal changes were confined to the primary visual areas and closely followed the gray matter contour. In both maps, a spatially defined band of elevated signal changes was centered over layer IV as defined anatomically in panel c. magnetic fields have made unique contributions to this development. Morphological images of brain tissue rely largely on proton density, T 1 , and T 2 differences between tissue types (eg, white matter vs. gray matter, cortex vs. subcortical nuclei etc.). Proton density is clearly a magnetic field independent parameter. However, relaxation times T 1 and T 2 are field dependent, generally increasing 63, 64 and decreasing 1,9,65,66 respectively, with higher magnetic fields (see review in ref 67) . It was recently shown that, contrary to expectations, the dispersion in T 1 increases with increasing magnetic fields in the brain, leading to superior T 1 -weighted structural images at the higher magnetic fields. 68 Lengthening of T 1 with increasing magnetic field also holds true for blood. Blood T 1 is virtually insensitive to its oxygenation state. Ex vivo measurements have shown that blood T 1 varies linearly with field strength going from 1.5 T to 9.4 T according to T 1 = 1.226+ 0.134B 0 . 69 This imparts a clear benefit in time-of-flight type vascular imaging, as well as perfusion imaging using spin labeling techniques. Mapping signals in all hemodynamic-based functional imaging methods, such as fMRI and optical imaging with intrinsic signals, are mediated through the vasculature. Consequently, vascular components in these methods are of utmost significance in determining the ultimate spatial and temporal accuracy of the neural activity maps produced by these methods. Therefore, it is important to be able to image vasculature in great detail, and ideally together with functional data in order to understand more precisely the source of the fMRI signals and their spatial correlation with the volume of altered neuronal activity. Vascular imaging with high resolution is also of paramount importance in other fields of biomedical research such as tumor biology, where angiogenesis is a necessary component of tumor growth. Taking advantage of the gains in SNR and longer T 1 values, the feasibility of obtaining high-resolution MR images of intracortical vessels was demonstrated in the cat brain. 70 This accomplishment relied on a combination of time-of-flight MR angiography and T 2 *-weighted contrast based on both endogenous BOLD effect and exogenous iron-oxide particles. It was possible to image vessels smaller than 100 microns, and distinguish between arteries and veins within the cortex 70 ( Figure 2 Such methods can be used for building models of the vascular network and may benefit a variety of research applications including fMRI, cerebrovascular disease, and cancer angiogenesis. Because of the lengthening T 1 , and increased SNR, significant gains can be expected for such studies at even higher magnetic fields such as ~16 to 17 T. At higher magnetic fields such as 14 to 17 T, other unique contrast mechanisms also come into play, leading to exquisite anatomical images obtained using approaches such as phase 71 and T 2 *-weighted imaging, providing unprecedented visualization of anatomy in animal models. 72 The mechanism responsible for this improved anatomical imaging appears to be tissue-specific differences induced largely by myelin content and/or presence of iron. [73] [74] [75] [76] [77] Thus, the primary advantage of ultrahigh field for structural MRI is not just the SNR gain, which could be traded for increased spatial resolution at constant imaging times or imaging time at constant spatial resolution, but also gains in contrast mechanisms. A recent and exciting example where the advantages of combined use of high magnetic fields and animal models were indispensable in morphological imaging has been the in vivo detection of amyloid plaques 78, 79 (Figure 3 ) exploiting the genetic capabilities available in animal models. Among the neurodegenerative disorders, Alzheimer's disease has received much of the attention due to its frequency and hence high public health impact. Aβ plaques, a cardinal pathologic feature of Alzheimer's disease, were previously observed in T 2 *-weighted images of ex vivo tissue specimens taken from the brain of AD mice. These plaques were imaged for the first time in vivo in anesthetized AD mice in reasonable imaging times (~1 hour) 78 using T 2 weighting at very high magnetic fields (9.4 T), incorporating strategies that minimize perturbations originating from breathing and brain pulsation. The mechanism responsible for this accomplishment is thought to be alterations in effective T 2 by diffusion-induced dynamic averaging of magnetic susceptibility gradients around the plaques. This contrast is small but depends quadratically on magnetic field magnitude. As such, the ultrahigh field was indispensable. Imaging of labeled plaques has been accomplished with other non-MR modalities (see references in ref 78) . Unlike other modalities, however, MRI provides the potential for visualizing individual plaques non-invasively.
High field MR spectroscopy with protons
Neurochemical profiling in the animal brain Proton (ie, 1 H) MRS, based on the proton resonance of hydrogen atoms, received considerable amount of attention in biomarker studies of neurological and psychiatric diseases 80 because it enables noninvasive detection of a number of endogenous small molecular weight neurochemicals directly in affected brain regions (eg, see detailed reviews in refs [81] [82] [83] . Depending on the acquisition parameters, up to five neurochemicals can be quantified reliably from human brain at 1.5 T. Animal model studies at very high magnetic fields, where spectral resolution and sensitivity are enhanced, were critical in demonstrating the feasibility of going beyond this. Early studies employed animal brain tissue extracts at high-field MR instruments demonstrating the wealth of biochemical information available by MRS. [84] [85] [86] [87] With recent advances in high-field MR instrumentation, spectroscopy localization techniques and sophisticated spectral quantification methods, however, the sensitivity and resolution of in vitro MRS was approached in the in vivo animal and human brain. 83 Ten to fifteen neurochemicals in the human brain 88, 89 and up to eighteen neurochemicals in the rat brain 90 can now be quantified noninvasively by high field MRS. In the mouse, which is highly desirable because of the availability of many models of human diseases, measurement of a 16-component neurochemical profile from 5-10 L volumes has been feasible. 91 The mouse brain studies encounter major challenges in MR instrumentation and methodology. 85, 92 However, these difficulties were overcome in the last decade. The ability to measure an extended "neurochemical profile" increases the likelihood of identifying underlying processes on the molecular level, to detect disease-specific metabolic signatures and to directly assess mechanisms of drug actions, eg, by measuring endogenous antioxidant levels to assess effects of antioxidant medications. 93 The technical and methodological challenges of MRS at high magnetic fields and the strategies to overcome them in order to fully benefit from increased sensitivity and chemical shift dispersion at high fields have been recently reviewed. 94 The quantification precision of MRS is improved at high fields, 89, [95] [96] [97] which is critical for preclinical and clinical applications.
T r a n s l a t i o n a l r e s e a r c h
The most frequently studied MRS biomarker N-acetylaspartate (NAA) is localized almost exclusively to neurons and is used as a surrogate for neuronal cell number and viability. 98, 99 Decreased NAA levels have been demonstrated in numerous neurological conditions and, therefore, are not very specific. 80 Neurotransmitters glutamate and γ-aminobutyric acid (GABA), which offer potentially more specific information about neuronal status, have also been reliably quantified in vivo with high field MRS. Glutamate is primarily localized to neurons, 100 with the highest levels present in excitatory terminals of glutamatergic neurons. 101 Decreased glutamate levels were observed in parallel with NAA in several neurological diseases and disease models, 85, 102, 103 likely because glutamatergic neurons make up the majority of neurons in the central nervous system (CNS). However, MRS detects both the neurotransmitter and metabolic pools of glutamate and alterations of glutamate levels in the absence of parallel NAA changes are possible. 86, 104 Most inhibitory neurons in the CNS are GABAergic and have low levels of glutamate in their cell bodies and processes. 101 GABA is potentially a good marker for these neurons because GABA concentrations and GABA-like immunoreactivity are highest in these neurons. 105, 106 In addition to neuronal markers, MRS enables detection of several putative glial markers: cell culture studies suggested a primarily glial localization for myo-inositol 107 and its levels were increased with gliosis in the monkey and rat brain. 86, 108 Therefore, increased myo-inositol levels have often been attributed to gliosis in neurological disorders. 102, [109] [110] [111] However, the glial localization of myoinositol has been disputed 112 and its levels do not always correlate with reactive astrogliosis. 113 Myo-inositol has multiple functions in cells. For example it plays an essential role in the regulation of cell volume in CNS as one of the most important organic osmolytes 112 and therefore may mark various cellular changes. An alternative glial marker is glutamine, which can be reliably quantified using high field MRS. Glutamine is preferentially localized in glial cells, 100, 101 and elevated glutamine levels were detected in diseases in which gliosis is known to occur. 102, 109 Total creatine (creatine + phosphocreatine, tCr) and choline-containing compounds (tCho) are also highly concentrated in glial cells 114 and therefore may also increase with gliosis. Since both neurons and glia contain creatine and phosphocreatine, tCr has been utilized as a measure of total cellular density and its increase has been interpreted as glial proliferation that is not counterbalanced by neuroaxonal loss. 111, 115 Choline-containing compounds, on the other hand, may also become increasingly MR visible with increased membrane turnover or breakdown, such as during active demyelination. 109, 116 Therefore, tCr and tCho changes may have multiple implications that need to be determined for each disease in question. In addition to the putative neuronal and glial markers, MRS can provide insights into energetic status and inflammation. For example, changes in the phosphocreatine-to-creatine ratio may be indicative of disturbances in energy metabolism. 117, 118 Lactate increases can be associated with anaerobic metabolism of infiltrating macrophages or indicate impaired mitochondrial function. 109, 116 MRS at high magnetic fields also allows the quantification of the most prominent antioxidants glutathione and vitamin C 88, 89, 119 and, thereby, can provide markers of oxidative stress. MRS studies using animal models of human diseases facilitate biomarker identification and drug development because they allow delineation of the pathological correlates of biomarkers and screening of potential drugs in preclinical trials. As such, these animal studies enhance human applications of MRS, however, the interpretation and translation of animal data to human applications need additional considerations. First, the regional differences and developmental changes in metabolite levels 120 need to be taken into account when designing studies. Of note, the neurochemical profile of the rodent and human brain is very similar, with only few differences, such as very high taurine levels in the rodent brain (Figure 4) . Second, potential effects of anesthesia, which is necessary for animal scanning, need to be considered. General anesthesia was not found to affect steady-state levels of MRS detectable metabolites in the brain, except for glucose and lactate. 121, 122 Diagnosis MRS can be utilized in preclinical and eventually clinical applications to distinguish, for example, transgenic mouse models from wild-type (WT) animals or patients from healthy controls. For the successful translation of biomarker data from animal models to humans, 123 not only does the model need to faithfully reproduce the pathology and phenotype of the human disease, but the same biomarker alterations need to be observed in the mouse model and in patients. This is a critical consider-ation. MRS studies with various AD mouse models demonstrate this issue well. For example, among the different AD models studied with 1 H MRS, APP-PS1 mice match the neurochemical profile found in human AD best. 103 These mice display reductions in NAA and glutamate, as well as an increase in myo-inositol. The myoinositol difference in particular had not been detected in other AD models, but is a prominent neurochemical alteration detected in human AD. 110 A more recent study demonstrated these neurochemical profile changes at an even earlier age than the APP-PS1 mice in a different AD mouse model. 124 In MPTP-intoxicated mice, well-accepted model of the dopaminergic denervation in Parkinson's disease (PD), high field MRS enabled detection of elevated glutamate, glutamine and GABA levels in the striatum. 125 Of these alterations, the GABA difference was confirmed in human PD at ultra-high field. 126 Longitudinal changes in neurochemical profiles were also reported in transgenic 117 and knock-in 118,127 mouse models of Huntington's disease (HD). The observed neurochemical changes varied between different mouse models 128 and relative to exploratory observations in human HD at 7 T, 129, 130 which underlines the need for development of HD mouse models that fully mimic the phenotype and pathology of human HD. While conventional structural MRI detects neuronal loss and atrophy, 1 H MRS can be utilized to assess neuronal dysfunction, ie, it can reveal biochemical changes that may start years before symptoms and irreversible neuron loss in neurological diseases, 131 thereby facilitating early diagnosis in these diseases. Recent work on a transgenic mouse model of spinocerebellar ataxia 1 (SCA1) clearly demonstrated this potential to detect early neurochemical alterations by MRS. The SCA1 model used in these studies reproduces the Purkinje cell pathology seen in patients and develops progressive ataxia similar to the human phenotype. 132 Importantly, the same neurochemical alterations were detected by MRS in this model 133 and patients with SCA1
134 ( Figure 5 ). Furthermore, these neurochemical alterations were already detectable in the presymptomatic disease stage and marked neuronal dysfunction and dendritic atrophy, rather than cell loss, as shown by correlative histopathology. 133 These data indicate that MRS at very high magnetic fields may have a role in early diagnosis of neurological diseases in the clinic.
Monitoring of disease progression
MRS has been widely utilized for noninvasive monitoring of neurochemical alterations associated with disease progression in animal models and increasingly at high and ultra-high fields. For example, MRS was successfully applied in longitudinal studies of mouse models of various neurodegenerative diseases. 103, 117, 118, 124, 127, 128, 133 These studies demonstrated that changes in multiple neurochemicals associated with neurodegeneration, compromised neurotransmission, energy production, and osmotic regulation, can be monitored with high sensitivity using MRS in affected brain regions. In addition, such neurochemical changes correlate with semi-quantitative measures of pathological burden, 133, 135 but precede tissue atrophy, 117, 133 as well as clear behavioral symptoms. 133 In a SCA1 study, remarkably, the same neurochemicals (NAA, myo-inositol, and glutamate) correlated with the ataxia score in patients 134 and with the pathology scores in the mouse model, 133 indicating these metabolites as biomarkers of disease progression and substantiating an ability to translate the mouse findings to patients. Concentrations ± SD (µmol/g) obtained from the cerebellum of 16 healthy volunteers (35±15 years old) and 6 mice (C57BL/6, 6-8 weeks old) at 4T and 9.4T, respectively. The concentrations in the mouse brain were taken from Tkáč et al. 91 The same pulse sequence (STEAM) was used for mouse and human data with the following parameters: echo time TE =5 ms at 4T, 2 ms at 9.4T; repetition time TR =4.5 s at 4T, 5 s at 9.4T; voxel size 6.2 mL at 4T, 6.1 µL at 9.4T. GABA, γ-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; GSH, glutathione; Ins, myo-inositol; Lac, lactate; Tau, taurine; NAA, N-acetylaspartate; tCho, total choline; tCr, total creatine GABA Glc Gln Glu GSH Ins Lac Tau NAA tCho tCr Glu + Gln
Monitoring of treatment and medication effects
Due to the ability to monitor neurochemistry longitudinally and noninvasively, MRS can also be used to monitor disease-modifying effects of treatments directly in affected brain regions and has been utilized in a number of preclinical disease and treatment models. Motivated by prior work that suggested nonsteroidal anti-inflammatory drugs (NSAIDs) may affect the incidence and progression of AD, the effects of chronic NSAID treatment was studied in a transgenic AD mouse model. 135 A significant protection against NAA and glutamate loss was demonstrated, suggesting that NSAIDs can protect against the neuronal pathology in AD. Similarly, dopamine administration, which had been the first-line pharmacologic treatment for PD for many years, reversed the abnormal striatal neurochemical levels (glutamate, glutamine, and GABA) in a PD model to WT levels. 125 In a SCA1 model, conditional expression of the transgene was utilized to establish the sensitivity of MRS biomarkers to disease reversal. 136 Namely, doxycycline treatment to suppress transgene expression was T r a n s l a t i o n a l r e s e a r c h 272 shown to reverse the abnormal neurochemical concentrations towards control levels. 136 Furthermore, the potential to monitor treatment effects in individual mice by utilizing multiple neurochemical levels at once was demonstrated in this study. In addition to longitudinal studies with chronic treatments, MRS can be utilized to monitor acute effects of drugs by obtaining time courses of metabolite levels. For example, neurochemical changes, including transient ones, upon acute phencyclidine (PCP) administration were captured in the rat brain, suggesting that MRS can be used to assess the effects of potential antipsychotic drugs in vivo. 137 Similarly, the effects of the antiepileptic drug vigabatrin on GABA levels were investigated in rat models using MRS, 138 and increases similar to those observed in the human brain 139 were detected. 17 O nucleus is elevated ~4 fold in conducting biological samples, including the rat brain, with magnetic field in going from 4.7 T to 9.4 T 140 while relaxation rates do not change. The SNR gain is within experimental error of expected theoretical maximum of 3.4 141 for these low frequencies since sample noise does not dominate SNR at these frequencies even in conducting samples. The biological information content in MR studies conducted with such low gyromagnetic nuclei can be unique. For example, the ability to image and quantitatively measure CMRO 2 in the rat 140, [142] [143] [144] and cat 145 was demonstrated and used to measure oxygen consumption changes associated with neuronal activity to obtain functional images using 17 O MR (Figure 6 ). Similarly, 13 C and 31 P experiments have demonstrated the feasibility of measuring glutamatergic neurotransmission rates, 5, 146, 147 cerebral glycogen turnover, [148] [149] [150] [151] [152] glucose transport kinetics, 17, [153] [154] [155] [156] oxidative ATP synthesis rate, 157 and metabolic alterations in disease states.
Low gyromagnetic ratio nuclei
158,159
Conclusion
Animal model studies have played a critical role in evaluating the potential of the MR imaging and spectroscopy techniques to study basic brain function, brain diseases, and mechanisms underlying neuroimaging. Very high magnetic fields have been indispensable for achieving important gains in biological information content in these studies. The introduction of latest generation of MR systems operating at magnetic fields ranging from ~11 to 17 Tesla is expected to advance the field further for animal model experiments. O to map % change in cerebral metabolic rate for oxygen (CMRO 2 ) vs blood oxygen level-dependent (BOLD) in the cat brain. 
